Next Article in Journal
Rotavirus A in Brazil: Molecular Epidemiology and Surveillance during 2018–2019
Previous Article in Journal
Functional and Mass Spectrometric Evaluation of an Anti-Tick Antigen Based on the P0 Peptide Conjugated to Bm86 Protein
Previous Article in Special Issue
Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region
Open AccessArticle

Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment

1
Department of Medical Biochemistry, Medical University of Lodz, 90-419 Lodz, Poland
2
Department of Infectious Diseases and Hepatology, Medical University of Lodz, 90-419 Lodz, Poland
*
Author to whom correspondence should be addressed.
Pathogens 2020, 9(6), 514; https://doi.org/10.3390/pathogens9060514
Received: 30 April 2020 / Revised: 8 June 2020 / Accepted: 22 June 2020 / Published: 25 June 2020
(This article belongs to the Special Issue Hepatitis C Virus Infections)
The hepatitis C virus (HCV) is known as a main etiological cause of chronic hepatitis. HCV infection disturbs cholesterol metabolism of the host, which is frequently observed in patients suffering from chronic hepatitis C (CHC). The course of viral infections remains under strict control of microRNA (miRNA). In the case of HCV, miR-122 exerts a positive effect on HCV replication in vitro. The purpose of this study was to investigate the impact of peginterferon alpha (pegIFN-α) and ribavirin treatments on the expression of miR-122 and the cholesterol level in the peripheral blood mononuclear cells (PBMCs) of CHC patients. We report here that the level of miR-122 expression in the PBMCs decreased after the antiviral treatment in comparison to the pretreated state. Simultaneously, the level of cholesterol in the PBMCs of CHC patients was higher six months following the treatment than it was pretreatment. Consequently, it seems that the decrease of miR-122 expression in the PBMCs of CHC patients is one of the antiviral effects connected with the pegIFN-alpha/ribavirin treatments. View Full-Text
Keywords: HCV; cholesterol; miR-122; PBMCs; pegIFN-alpha; ribavirin HCV; cholesterol; miR-122; PBMCs; pegIFN-alpha; ribavirin
Show Figures

Figure 1

MDPI and ACS Style

Sidorkiewicz, M.; Grek-Kowalinska, M.; Piekarska, A. Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment. Pathogens 2020, 9, 514.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop